US testing outfit Sequential Skin has entered into a collaboration agreement with Johnson & Johnson to measure skin health for personal care products.
The partnership with Johnson & Johnson's consumer business will focus on Sequential developing new methods for non-invasive genomic-based skin testing to help it add to its growing database of skin samples.
Sequential’s in-house lab analysis tests inform on the efficacy of products for everything from aging to acne, while measuring impact at a molecular level.
“Our collaboration with Johnson & Johnson will give us the opportunity to improve upon our novel technologies at Sequential, to further understand how molecular changes on the skin may translate to skin and human health,” said Sequential CEO and co-founder Oliver Worsley (pictured, left).
“Consumers today are seeking greater transparency and confidence around product claims. Our mission as an ally to top personal care industry brands is to empower them with proper evidence and real scientific data on the microbiome to substantiate their product benefits so consumers can make better-informed decisions about their skin health,” he added.
“To do this, we have developed a proprietary end-to-end skin microbiome next-generation testing platform, with an ability to do further validation and quantitative analysis with our in-house Smart Probes."
